Tumor lysis syndrome (TLS) is 1 of the complications that usually follows chemotherapy treatment of myelo-lymphoproliferative diseases. Corticosteroids (CS) could also induce TLS in this type of malignancies. On the other hand, TLS in solid tumors is less frequent, and CS treatment was never reported to be associated with TLS in solid tumor. Here we report the first case of TLS in a solid tumor (melanoma) after CS treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00000441-200203000-00007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dendritic cells type 1 control the formation, maintenance, and function of tertiary lymphoid structures in cancer.
bioRxiv
December 2024
Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Tertiary lymphoid structures (TLS) are organized immune cell aggregates that arise in chronic inflammatory conditions. In cancer, TLS are associated with better prognosis and enhanced response to immunotherapy, making these structures attractive therapeutic targets. However, the mechanisms regulating TLS formation and maintenance in cancer are incompletely understood.
View Article and Find Full Text PDFTertiary lymphoid structures in high-grade serous tubo-ovarian carcinoma: anatomical site matters.
Cancer Immunol Immunother
January 2025
Division of Oncology, Department of Clinical Sciences Lund, and Lund University Cancer Center, Lund University, Lund, Sweden.
Tertiary lymphoid structures (TLS) in the tumor microenvironment are prognostically beneficial in many solid cancer types. Reports on TLS in high-grade serous tubo-ovarian carcinoma (HGSC) are few, and the prognostic impact is unclear. We investigated mature TLS (mTLS), immature TLS (iTLS) and lymphoid aggregates (LA) in primary adnexal tumors (PTs) and synchronous omental/peritoneal metastases (pMets) of HGSC.
View Article and Find Full Text PDFSuccessful treatment of tumor lysis syndrome associated with hepatic artery infusion chemotherapy in a patient with hepatocellular carcinoma: a case report.
J Med Case Rep
December 2024
Liver Cancer Institute, National Clinical Research Center for Interventional Medicine, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai, 200032, People's Republic of China.
Background: Tumor lysis syndrome is a life-threatening complication in the treatment of cancer. However, it rarely occurs in solid tumors, especially in hepatocellular carcinoma.
Case Presentation: We present a 52-year-old male Asian patient with advanced hepatocellular carcinoma treated with hepatic artery infusion chemotherapy that resulted in tumor lysis syndrome.
Spontaneous Tumor Lysis Syndrome in an Undifferentiated Uterine Sarcoma: A Case Report and Review of the Literature.
Clin Case Rep
December 2024
Department of Internal Medicine, School of Medicine Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS) Tehran Iran.
Tumor lysis syndrome (TLS), as an oncologic emergency, may rarely occur in patients with solid organ neoplasms and without previous cancer therapy. Physicians should be highly aware of the possibility of TLS, with special attention in patients having bulky tumors, irrespective of recent treatment with cytotoxic agents for its prompt prevention and treatment.
View Article and Find Full Text PDFTumor Lysis Syndrome in a 30-Year-Old Male With Metastatic Seminoma: A Case Report.
Cureus
November 2024
Internal Medicine, Rutgers University New Jersey Medical School, Newark, USA.
Article Synopsis
- * He underwent a left radical orchiectomy and began chemotherapy with bleomycin, etoposide, and cisplatin, developing signs of tumor lysis syndrome (TLS) before treatment.
- * The patient was treated with IV normal saline and allopurinol to stabilize his uric acid and potassium levels, highlighting the need for monitoring TLS in patients with extensive tumor burden prior to chemotherapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!